{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:13Z","timestamp":1794047353659,"version":"4.8.0"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"2","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2020.249276","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T17:30:59Z","timestamp":1587058259000},"page":"619-621","source":"Crossref","is-referenced-by-count":5,"title":["SMAD1 promoter hypermethylation and lack of SMAD1 expression in Hodgkin lymphoma: a potential target for hypomethylating drug therapy"],"prefix":"10.3324","volume":"106","author":[{"family":"Magdalena M. Gerlach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Anna Stelling-Germani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Cheuk Ting Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sebastian Newrzela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Claudia D\u00f6ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Visar Vela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Anne M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sylvia Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Alexandar Tzankov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"20803","doi-asserted-by":"crossref","unstructured":"Poppema S. Immunobiology and pathophysiology of Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program. 2005;231-238.","DOI":"10.1182\/asheducation-2005.1.231"},{"key":"20804","doi-asserted-by":"crossref","unstructured":"Liu Y, Zhang P, Li J, Kulkarni AB, Perruche S, Chen W. A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat Immunol. 2008; 9(6):632-640.","DOI":"10.1038\/ni.1607"},{"key":"20805","doi-asserted-by":"crossref","unstructured":"Chiu J, Ernst DM, Keating A. Acquired natural killer cell dysfunction in the tumor microenvironment of classic Hodgkin lymphoma. Front Immunol. 2018; 9:267.","DOI":"10.3389\/fimmu.2018.00267"},{"key":"20806","doi-asserted-by":"crossref","unstructured":"Menter T, Tzankov A. Lymphomas and their microenvironment: a multifaceted relationship. Pathobiology. 2019; 86(5-6):225-236.","DOI":"10.1159\/000502912"},{"key":"20807","doi-asserted-by":"crossref","unstructured":"Stelling A, Wu CT, Bertram K. Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma. Blood Adv. 2019; 3(20):3020-3032.","DOI":"10.1182\/bloodadvances.2019000210"},{"key":"20808","doi-asserted-by":"crossref","unstructured":"Tzankov A, Matter MS, Dirnhofer S. Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology. 2010; 77(6):301-308.","DOI":"10.1159\/000321567"},{"key":"20809","doi-asserted-by":"crossref","unstructured":"Lebman DA, Edmiston JS. The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes. Microbes Infect. 1999; 1(15):1297-1304.","DOI":"10.1016\/S1286-4579(99)00254-3"},{"key":"20810","doi-asserted-by":"crossref","unstructured":"Gholiha AR, Hollander P, Hedstrom G. High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms. Br J Haematol. 2019; 184(2):192-201.","DOI":"10.1111\/bjh.15703"},{"key":"20811","doi-asserted-by":"crossref","unstructured":"Juskevicius D, Jucker D, Dietsche T. Novel cell enrichment technique for robust genetic analysis of archival classical Hodgkin lymphoma tissues. Lab Invest. 2018; 98(11):1487-1499.","DOI":"10.1038\/s41374-018-0096-6"},{"key":"20812","doi-asserted-by":"crossref","unstructured":"Swerev TM, Wirth T, Ushmorov A. Activation of oncogenic pathways in classical Hodgkin lymphoma by decitabine: a rationale for combination with small molecular weight inhibitors. Int J Oncol. 2017; 50(2):555-566.","DOI":"10.3892\/ijo.2016.3827"},{"key":"20813","doi-asserted-by":"crossref","unstructured":"D'Al\u00f2 F, Leone G, Hohaus S. Response to 5-azacytidine in a patient with relapsed Hodgkin lymphoma and a therapy-related myelodysplastic syndrome. Br J Haematol. 2011; 154(1):141-143.","DOI":"10.1111\/j.1365-2141.2010.08438.x"},{"key":"20814","doi-asserted-by":"crossref","unstructured":"Foulks JM, Parnell KM, Nix RN. Epigenetic drug discovery: targeting DNA methyltransferases. J Biomol Screen. 2012; 17(1):2-17.","DOI":"10.1177\/1087057111421212"},{"key":"20815","doi-asserted-by":"crossref","unstructured":"Munoz O, Fend F, de Beaumont R, Husson H, Astier A, Freedman AS. TGFbeta-mediated activation of Smad1 in B-cell non-Hodgkin's lymphoma and effect on cell proliferation. Leukemia. 2004; 18(12):2015-2025.","DOI":"10.1038\/sj.leu.2403485"},{"key":"20816","doi-asserted-by":"crossref","unstructured":"Wood VH, O'Neil JD, Wei W, Stewart SE, Dawson CW, Young LS. Epstein-Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGFbeta signaling pathways. Oncogene. 2007; 26(28):4135-4147.","DOI":"10.1038\/sj.onc.1210496"},{"key":"20817","doi-asserted-by":"crossref","unstructured":"Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V. Tumor-specific T cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma. J Clin Oncol. 2018; 36(11):1128-1139.","DOI":"10.1200\/JCO.2017.74.3179"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9721\/70784","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9721\/70785","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9721\/70784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:56:45Z","timestamp":1794045405000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2020.249276","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,16]]}}}